Page 282 - Vitamin D and Cancer

11 Vitamin D and Hematologic Malignancies 269

working through different pathways, could lead to synergistic activity. Proof of
principle that 1,25(OH) D and its analogs are beneficial in cancer has been vali-
2 3
dated in experiments conducted in vitro and in laboratory animals. However, to date
their therapeutic value in patients is unproven.

References

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B,
Kastner P, Mark M, Chambon P, Evans RM (Dec 15,1995) The nuclear receptor superfamily:
the second decade. Cell 83(6):835–9
2. Christakos S, Raval-Pandya M, Wernyj RP, Yang W (June 1, 1996) Genomic mechanisms
involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 316(Pt
2):361–71
3. Koren R, Ravid A, Liberman UA, Hochberg Z, Weisman Y, Novogrodsky A (Nov,1985)
Defective binding and function of 1,25-dihydroxyvitamin D3 receptors in peripheral mono-
nuclear cells of patients with end-organ resistance to 1,25-dihydroxyvitamin D. J Clin Invest
76(5):2012–5
4. Koeffler HP, Bishop JE, Reichel H, Singer F, Nagler A, Tobler A, Walka M, Norman AW (Mar
26, 1990) Lymphocyte cell lines from vitamin D-dependent rickets type II show functional
defects in the 1 alpha,25-dihydroxyvitamin D3 receptor. Mol Cell Endocrinol 70(1):1–11
5. Kizaki M, Norman AW, Bishop JE, Lin CW, Karmakar A, Koeffler HP (Mar 15,1991)
1,25-Dihydroxyvitamin D3 receptor RNA: expression in hematopoietic cells. Blood
77(6):1238–47
6. Langub MC, Reinhardt TA, Horst RL, Malluche HH, Koszewski NJ (Sep,2000) Characterization
of vitamin D receptor immunoreactivity in human bone cells. Bone 27(3):383–7
7. Zerwekh JE, Yu XP, Breslau NA, Manolagas S, Pak CY (Oct,1993) Vitamin D receptor
quantitation in human blood mononuclear cells in health and disease. Mol Cell Endocrinol
96(1–2):1–6
8. Takahashi K, Nakayama Y, Horiuchi H, Ohta T, Komoriya K, Ohmori H, Kamimura T
(Aug,2002) Human neutrophils express messenger RNA of vitamin D receptor and respond
to 1alpha,25-dihydroxyvitamin D3. Immunopharmacol Immunotoxicol 24(3):335–47
9. Hewison M, Freeman L, Hughes SV, Evans KN, Bland R, Eliopoulos AG, Kilby MD, Moss
PA, Chakraverty R (June 1, 2003) Differential regulation of vitamin D receptor and its ligand
in human monocyte-derived dendritic cells. J Immunol 170(11):5382–90
10. Kreutz M, Andreesen R, Krause SW, Szabo A, Ritz E, Reichel H (Aug 15,1993) 1,25-dihy-
droxyvitamin D3 production and vitamin D3 receptor expression are developmentally regu-
lated during differentiation of human monocytes into macrophages. Blood 82(4):1300–7
11. Favus MJ, Kamauskas AJ, Parks JH, Coe FL (Oct,2004) Peripheral blood monocyte vitamin
D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol
Metab 89(10):4937–43
12. Nakajima S, Yamaoka K, Yamamoto T, Okada S, Tanaka H, Seino Y (Sep,1990) Decreased
concentration of 1,25-dihydroxyvitamin D3 receptors in peripheral mononuclear cells of
patients with X-linked hypophosphatemic rickets: effect of phosphate supplementation.
Bone Miner 1 0(3):20 1–9
13. Lee Y, Inaba M, DeLuca HF, Mellon WS (Aug 15,1989) Immunological identification of
1,25-dihydroxyvitamin D3 receptors in human promyelocytic leukemic cells (HL-60) during
homologous regulation. J Biol Chem 264(23):13701–5
14. Gocek E, Kielbiński M, Marcinkowska E (May 1,2007) Activation of intracellular signaling
pathways is necessary for an increase in VDR expression and its nuclear translocation. FEBS
Lett 581(9):1751–7